PMID- 37975251
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240123
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 24
DP  - 2023 Dec
TI  - Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, 
      real-world study.
PG  - 21725-21734
LID - 10.1002/cam4.6733 [doi]
AB  - BACKGROUND: Brentuximab vedotin (BV) was approved as a therapy for patients with 
      CD30-positive lymphoma in China in 2020 based on the results of multiple clinical 
      trails. Few Chinese real-world data of its use are yet available. Herein, we 
      present the application situation of BV in patients with lymphoma among different 
      hospitals in Henan province in China under real-world conditions. METHODS: This 
      was a multicenter and retrospective study in 104 patients with lymphoma who 
      received BV for the first time between August 2020 and September 2022 across 
      eight centers in Henan province. Data on the clinical use, effectiveness and 
      adverse events (AEs) of BV were extracted from patient medical records. 
      Short-term effectiveness was assessed based on objective response rate (ORR), 
      complete response (CR), partial response (PR), stable disease (SD) and 
      progressive disease (PD). Progression-free survival (PFS) and overall survival 
      (OS) were calculated using Kaplan-Meier method. Safety was also evaluated in our 
      study. RESULTS: 104 lymphoma patients were enrolled in our study, who had 
      completed a median of two cycles (range,1-8) of BV-based treatment. A total of 
      72.1% of patients were relapsed/refractory (R/R) lymphoma, and only 27.9% were 
      previously untreated lymphoma who received BV in frontline treatment settings. 
      Among them who received effectiveness evaluation, the ORR achieved 64.5% (CR 
      25.8%, PR 38.7%). After a median follow-up of 11 months, the 6-month PFS rate and 
      OS rate achieved 77.2% and 90.1% respectively, and the 12-month PFS rate and OS 
      rate achieved 77.2% and 79.9% respectively. In general, BV-based treatment was 
      well-tolerated, with 38.5% incidence of grade >/=3 AEs. The most commonly reported 
      AEs were hematologic disorders, especially neutropenia, with the incidence 
      reaching 50.0%. CONCLUSIONS: BV-based regimens could be a promising therapeutic 
      option with remarkable effectiveness and moderate toxicity in treating Chinese 
      lymphoma patients with CD30 expression.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhang, Xudong
AU  - Zhang X
AD  - The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
FAU - Qiao, Honghan
AU  - Qiao H
AUID- ORCID: 0009-0009-1638-2238
AD  - The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
FAU - Chai, Xiaofei
AU  - Chai X
AD  - The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
FAU - Gao, Xue
AU  - Gao X
AD  - Henan Cancer Hospital, ZhengZhou, China.
FAU - Ma, Rongjun
AU  - Ma R
AD  - Henan Provincial People's Hospital, ZhengZhou, China.
FAU - Li, Yufu
AU  - Li Y
AD  - Henan Cancer Hospital, ZhengZhou, China.
FAU - Zhu, Zunmin
AU  - Zhu Z
AD  - Henan Provincial People's Hospital, ZhengZhou, China.
FAU - Zhang, Mingzhi
AU  - Zhang M
AUID- ORCID: 0000-0003-3581-551X
AD  - The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
LA  - eng
GR  - 81970184/National Natural Science Foundation of China/
GR  - 82070210/National Natural Science Foundation of China/
GR  - 82170183/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20231117
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 7XL5ISS668 (Brentuximab Vedotin)
RN  - 0 (Immunoconjugates)
SB  - IM
MH  - Humans
MH  - Brentuximab Vedotin/therapeutic use/adverse effects
MH  - *Hodgkin Disease
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Immunoconjugates/adverse effects
MH  - *Lymphoma/drug therapy/chemically induced
PMC - PMC10757088
OTO - NOTNLM
OT  - brentuximab vedotin
OT  - effectiveness
OT  - lymphoma
OT  - real-world study
OT  - safety
COIS- The authors declare no potential competing interests.
EDAT- 2023/11/17 15:25
MHDA- 2024/01/02 11:43
PMCR- 2023/11/17
CRDT- 2023/11/17 05:28
PHST- 2023/09/26 00:00 [revised]
PHST- 2023/05/16 00:00 [received]
PHST- 2023/10/12 00:00 [accepted]
PHST- 2024/01/02 11:43 [medline]
PHST- 2023/11/17 15:25 [pubmed]
PHST- 2023/11/17 05:28 [entrez]
PHST- 2023/11/17 00:00 [pmc-release]
AID - CAM46733 [pii]
AID - 10.1002/cam4.6733 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Dec;12(24):21725-21734. doi: 10.1002/cam4.6733. Epub 2023 Nov 
      17.